📊 AVIR Key Takeaways
Investment Thesis
Atea Pharmaceuticals shows explosive revenue growth of 622.5% YoY, indicating strong market demand for its products, but this growth masks severe operational challenges. The company is burning substantial cash with negative operating margins of -51.5%, negative free cash flow of -134.0M, and mounting losses despite massive revenue expansion, suggesting the business model is not yet viable at scale.
AVIR Strengths
- Exceptional revenue growth of 622.5% YoY demonstrates strong product-market fit and commercial traction
- Strong balance sheet with $95.7M cash and 7.82x current ratio providing runway for operations
- Minimal debt (0.00x debt-to-equity) and low financial leverage reduce bankruptcy risk
AVIR Risks
- Severe profitability crisis with -45.1% net margin and -50.2% ROA indicating unsustainable unit economics
- Negative free cash flow of -134.0M annually exceeds net loss, suggesting operational burn is accelerating and cash runway limited
- Operating losses of -180.9M despite strong revenue growth indicate inability to scale profitably, with gross margins and cost structure unviable
Key Metrics to Watch
- Operating margin trajectory toward breakeven as revenue scales
- Free cash flow trend and cash runway remaining at current burn rate
- Gross margin expansion to determine if revenue growth can translate to profitability
AVIR Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 7.82x current ratio provides a solid financial cushion.
AVIR Profitability Ratios
AVIR vs Healthcare Sector
How Atea Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
AVIR Balance Sheet & Liquidity
AVIR 5-Year Financial Trend
5-Year Trend Summary: Atea Pharmaceuticals, Inc.'s revenue has grown significantly by 622% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.00 indicates the company is currently unprofitable.
AVIR Growth Metrics (YoY)
AVIR Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2022 | $32.8M | $1.5M | $0.05 |
| Q2 2022 | $60.4M | $1.5M | $0.02 |
| Q1 2022 | $66.0M | $30.7M | $0.34 |
| Q3 2021 | $32.8M | $1.5M | $0.05 |
| Q2 2021 | $60.4M | $1.5M | $0.02 |
| Q1 2021 | $66.0M | -$4.0M | $0.34 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AVIR Capital Allocation
AVIR SEC Filings
Access official SEC EDGAR filings for Atea Pharmaceuticals, Inc. (CIK: 0001593899)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AVIR
What is the AI rating for AVIR?
Atea Pharmaceuticals, Inc. (AVIR) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are AVIR's key strengths?
Exceptional revenue growth of 622.5% YoY demonstrates strong product-market fit and commercial traction. Strong balance sheet with $95.7M cash and 7.82x current ratio providing runway for operations.
What are the risks of investing in AVIR?
Severe profitability crisis with -45.1% net margin and -50.2% ROA indicating unsustainable unit economics. Negative free cash flow of -134.0M annually exceeds net loss, suggesting operational burn is accelerating and cash runway limited.
What is AVIR's revenue and growth?
Atea Pharmaceuticals, Inc. reported revenue of $351.4M.
Does AVIR pay dividends?
Atea Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find AVIR SEC filings?
Official SEC filings for Atea Pharmaceuticals, Inc. (CIK: 0001593899) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AVIR's EPS?
Atea Pharmaceuticals, Inc. has a diluted EPS of $-1.94.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.